A randomized control trial with Nature Bright Sun Touch Plus


Background. Unipolar non-seasonal depressed patients with concomitant evening chrono- type were associated with poor clinical outcomes and higher non-remission rate. This study aims to examine the efficacy of adjunctive bright light therapy with gradual timing advance in a randomized, assessor and prescriber-blinded controlled trial.

Method. Participants were randomly allocated to receive 5 weeks of either bright white light therapy (BLT) or dim red light (DRL) with the same advancement protocol. Participants were followed up till 5 months after treatment. Primary outcomes included (i) remission rate and (ii) the severity of depression. The analysis was conducted using KaplanMeier survival ana- lysis, Cox proportional hazard analysis and linear mixed models.

Results. A total of 93 participants (46.4 ± 11.7 years old, 80% female) were randomized. The cumulative remission rate for the BLT and the DRL groups was 67.4% and 46.7%, respectively. Time to remission was shorter for the BLT group relative to the DRL group (log-rank test p = 0.024). Cox proportional hazard survival analysis showed that patients in the BLT group had a higher probability of achieving remission relative to patients in the DRL group [hazard ratio = 1.9 (95% CI = 1.13.4), p = 0.026]. Further sensitivity analysis demonstrated greater improve- ment in 17-Hamilton Depression Score (group × time interaction, p = 0.04) in the BLT group for those who were adherent to light therapy.

Conclusions. The use of bright light therapy with gradual advance protocol is an effective adjunctive treatment resulting in quicker and a higher rate of remission of depression in patients with non-seasonal unipolar depression and evening-chronotype.


© The Author(s) 2020. Published by Cambridge University Press


Major depressive disorder (MDD) is one of the most common mental illnesses with significant morbidities and mortalities. The current treatment goal is to achieve remission of the illness (Keller, 2003). Non-remission of depression not only leads to significant personal distress but also is associated with various adverse outcomes, including substantial psychosocial dis- ability, higher health care utilization (Judd et al., 2000), increased risk of relapse/recurrence (Judd et al., 1998) and suicidality (Li, Lam, Yu, Zhang, & Wing, 2010). By using the Morningness-Eveningness Questionnaires, subjects could be classified as the morning, inter- mediate, or evening-chronotype (a circadian preference for later bedtime and rise time) (Horne & Ostberg, 1976). About 20% of patients with unipolar non-seasonal depression were found to have evening-chronotype, and they had higher non-remission rate, worse depressive and insomnia symptoms, as well as higher suicidality, as compared to their counter- parts with intermediate/morning chronotypes (Chan et al., 2014). A recent meta-analysis fur- ther corroborated the findings that eveningness was associated with more severe depressive symptoms in the clinical populations with mood disorders (Au & Reece, 2017). Light therapy has been well established as an effective treatment for seasonal affective disorder (Pjrek et al., 2020). Two recent randomized controlled trials also showed that light treatment resulted in a higher remission of depressive symptoms in patients with non-seasonal depression (Lam et al., 2016; Sit et al., 2018). In addition, light therapy was shown to hasten the effect of antidepres- sants when used as an adjunctive treatment for non-seasonal depression patients (Benedetti et al., 2003; Lam et al., 2016; Martiny, 2004) but the effect of bright light therapy in depressive patients with evening-chronotype, i.e. those with poorer outcomes, has not been well studied. Apart from improving mood symptoms, light was shown to be effective in phase-shifting the 

human circadian rhythm (Boivin, Duffy, Kronauer, & Czeisler, 1996), and has been used as a treatment for phase advancing in patients with delayed sleep wake phase disorder (DSPD) (Dodson & Zee, 2010). As the phase-shifting effect of light depends critically on the timing of administration in relation to the circadian phase (Duffy & Czeisler, 2009), theoretically, the use of light therapy at an early fixed timing might risk an inad- vertent delay of the circadian rhythm in the patients with evening- chronotype. To address this issue, a protocol of gradual advance of the timing of light therapy according to the baseline habitual wake time and adherence to prescribed light therapy was tested in the current study. The aim of this study was to examine the efficacy of adjunctive light therapy with a gradual advance of tim- ing in evening-chronotype patients with non-seasonal unipolar depression. We hypothesized that the bright light therapy (BLT) group would have a greater improvement in depressive symptoms, a higher remission rate of depression, and other better clinical outcomes, e.g. less sleep disturbance and better quality of life, as compared to the control group (dim red light, DRL).


Study subjects

Participants were recruited from the psychiatric outpatient clinic of a university-affiliated hospital. Recruited participants were on a stable dose of psychotropic medications, and any change of medications during the intervention period of the study was recorded. Participants who met all the following criteria were eli- gible for the inclusion in the study: (i) Chinese aged 1865 years old; (ii) being capable of giving informed consent; (iii) meeting the diagnostic criteria of MDD according to Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998); (iv) scoring at least 14 on the 17-item Hamilton Depression Score (17-HDS) component from the Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS) (Williams & Terman, 2003); (vi) scor- ing 41 or less in the Morningness Eveningness Questionnaire (Horne & Ostberg, 1976) (i.e. evening chronotype). The exclusion criteria included: (i) MDD fulfilling the seasonal pattern specifier of the DSM-V; (ii) a current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic epi- sode, schizophrenia, personality disorder, mental retardation, or organic mental disorder; (iii) significant suicidal risk in the opin- ion of the investigator, or had moderate level or above suicidality as assessed by the Suicidality Module of MINI, or had made a sui- cide attempt in the past 3 months; (iv) a history of light induced migraine/epilepsy; (v) current use of photosensitizing medica- tions; (vi) presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma; (vii) current therapy with drugs that could potentially interfere with ones circadian rhythm, i.e. lithium, exogenous melatonin, melatonergic antidepressants within past 3 months; (viii) shift worker; (ix) trans-meridian flight in the past 3 months and during the study; (x) significant medical con- dition/hearing impairment/speech deficit which might lead to incapability of completing the clinical interview. All procedures contributing to this work comply with the ethical standards of the relevant institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving the patients were approved by the local clin- ical research ethics committee (CREC Ref No: 2014.505-T) and the trial was registered with the Chinese clinical trial registry 

ChiCTR-IOR-15006937). All subjects have given their written

informed consent after explanation of the study procedures.

Clinical assessments

Eligible participants were asked to complete 1-week sleep diary for prospective evaluation of their sleep-wake pattern. All the study participants were assessed at baseline and weekly during the 5 weeks of active intervention, as well as at 1-week post-treatment (P1w), 1-month post-treatment (P1 m), 2-month post-treatment (P2 m) and 5-month post-treatment (P5 m). The primary outcome measures were the rate of remission, as defined by 17-HDS of 7 or less. Secondary outcomes included anxiety symptoms as assessed by clinician-rated Hamilton Anxiety Rating Scale (HAM-A) (Maier, Buller, Philipp, & Heuser, 1988), and a battery of self-reported questionnaires including Hospital Anxiety and Depression Scale (HADS) (Leung, Wing, Kwong, Lo, & Shum, 1999), Insomnia Severity Index (ISI) (Bastien, Vallieres, & Morin, 2001), Beck Scale for Suicidal Ideation (BSSI) (Beck, Steer, & Ranieri, 1988), Chadler Fatigue Scale (CFS) (Chalder et al., 1993) and Short-Form 36 Health Survey (SF36) (Hays, Sherbourne, & Mazel, 1993). The self-reported questionnaires were translated and validated in Chinese (Lam, Gandek, Ren, & Chan, 1998; Leung et al., 1999; Li XY et al., 2010; Wong & Fielding, 2010; Yu, 2010). A higher rating in these clinical assessments indicated a worse clinical condition, except for SF36, at which a higher rating indicated a better health status. CFS and SF36 enquire symptoms over the past 1 month, and were administered at the baseline, fifth treatment week, P1 m, P2 m and P5 m only; while all other assessments were com- pleted at each follow-up visit. The adverse outcomes were moni- tored by a modified adverse event checklist (AEC), which included common side effects from light therapy based on the previous studies (Levitt et al., 1993; Martiny, 2004; Terman & Terman, 2005; Tuunainen, Kripke, & Endo, 2004). Participants were asked to fill in the AEC at baseline in order to differentiate pre-existing somatic symptoms from those treatment-emergent adverse events. The Young Mania Rating Scale (YMRS) (Young, Biggs, Ziegler, & Meyer, 1978) was used to monitor possible hypomanic/manic symptoms. At baseline, participants were asked to rate how much they believed the treatment would be effi- cacious in improving their mood symptoms on a Likert scale from 0 (not at all) to 100 (very much). They were asked to fill in a sleep diary for a week prior to each follow-up. Participants were also instructed to record the timing of light therapy received on the sleep diary. The timeline of intervention and follow-up was illu- strated in eFigure1 of the Supplementary Files.

Randomization and treatment blinding

Eligible participants were randomly allocated to either bright light therapy (BLT) group or dim red light (DRL) group according to a computer-generated random number sequence. An independent research worker performed the randomization and assignment of interventions. Participants were informed that the study aimed to compare two different kinds of light treatments but no declaration was made as to which treatment was the placebogroup. The prescription of light timing was determined and per- formed by a prescribing psychiatrist ( prescriber) who was blinded to the treatment allocation. A clinical assessor (assessor) who was also masked to the group allocation assessed the patients inde- pendently at baseline and each follow-up. The randomization

ist was not accessible to prescriber and assessor to ensure conceal- ment. The study participants were instructed not to reveal their allocated treatment to the assessor and prescriber.


Light therapy

Study participants in the BLT group received 5 weeks of daily bright light therapy lasting for 30 min, delivered by a light box sized 15.7′′H × 11′′W × 7.25′′D which emits 10 000 lux white light at eye level at a distance of 40 cm (SunTouch Plus; Nature Bright Company, CA, USA). For the participants in the dim red light (DRL group), they were prescribed 50 lux dim red light. The light boxes of the two groups looked identical when the light was off. The initial timing of light therapy was set at the habitual wake time, as determined by the prescriber based on the sleep diary prior to the baseline session.

Protocol for gradual advance in light therapy start time

Light therapy was started within 1 hour of the habitual wake time, which was inferred from the 1-week sleep diary prior to the base- line visit. Prescriber reviewed the sleep diary and light therapy recorded weekly to determine the timing of the light therapy for each participant. The timing of light therapy was gradually advanced 30 min each week only if the participants were able to adhere to the prescribed treatment adequately (i.e. greater than 50% of the total weekly duration of light therapy received over the past treatment week with timing overlapped with or earl- ier than the prescribed time of light therapy, which was defined as appropriately-timed LT). If the participant was not able to adhere to the prescribed timing in the previous week, the timing of light therapy would be kept the same in the following week. The advancement protocol in this study took into account the duration and timing of treatment received.

Statistical analysis

Sample size calculation was based on a previous study of adjunct- ive light therapy conducted in patients with non-seasonal depres- sion (Martiny, 2004). In order to achieve 95% two-sided confidence level, 80% power, the planned sample size was 44 par- ticipants in each arm. Given an estimation of 30% drop out rate, 57 participants were therefore required for each group. The ana- lysis was conducted on an intention-to-treat principle including all the participants who were allocated to treatment. The time to achieve remission and the cumulative remission rate over the 6 months were evaluated using KaplanMeier method and the log-rank test. Cox proportional hazard analysis was used to gen- erate the hazard ratios and corresponding 95% confidence inter- vals based on the KaplanMeier estimates. In order to better accommodate missing data without the need for imputation, we have performed analyses of the outcomes by linear mixed models (LMM). Variables that were not normally distributed were log- transformed prior to the mixed model analyses. Cohens d between-group effect sizes were estimated by dividing each rele- vant mixed model derived effect estimate by the baseline standard deviation of the dependent variable (Trockel, Karlin, Taylor, & Manber, 2014). The group differences in baseline clinical charac- teristics and the rates of adverse events (AE) were tested by Chi-square tests and t test as appropriate. All the statistical ana- lyses were performed using Statistical Package System Software for Windows 25.0 (SPSS, IBM Corp, Chicago, IL, USA).


A total of 114 participants with moderate unipolar non-seasonal MDD and evening-chronotype were recruited into this study from September 2015 to December 2018. Although 114 participants fulfilled the study criteria and completed baseline, nine of them subsequently refused to participate further and 12 had spontan- eous remission (i.e. 17-HDS scored 7 or less at randomization). Ninety-three participants were then randomly allocated to two groups: 47 to the BLT group and 46 to the dim red light (DRL) group. Data of all 93 participants were analyzed. (Fig. 1).

Baseline demographic and clinical characteristics

As shown in Table 1, the mean age of the participants was 46.4 ± 11.7 (mean ± S.D.) years old and 80% were female. The average duration of depressive illness was 13.7 ± 11.0 (mean ± S.D.) years. There were no differences in the baseline clinical characteristics, types of prescribed medication and the sleep diary parameters between the two groups, except that there was a slight female pre- ponderance in the DRL group (89% v. 70%, p=0.02). The 17-HDS was in the range of moderate severity of depression (17-HDS, mean ± S.D.: 19.3 ± 6.8). All the recruited participants were of evening-chronotype (MEQ score, mean ± S.D.: 35.3 ± 6.7) which was consistent with their baseline sleep pattern of a late bedtime (mean ± S.D.: 01:21am ± 1:48) and late rise time (mean±S.D.: 10:25am±2:03). Of note, these participants also had moderate severity of insomnia (ISI score, mean ± S.D.: 16.8 ± 6.0). There was no significant difference in the expectation towards treatment at baseline between the two groups. These findings indi- cated that the BLT group had comparable demographic and clin- ical profiles to the DRL group.

Timing of light therapy and adherence

Both BLT and DRL groups were prescribed light therapy with a gradual advance in the start time over the course of the 5-week intervention (the main effect of time p<0.01), but the actual light therapy start time recorded by sleep diary in the BLT group was advanced significantly earlier than the DRL group (group × time interaction p = 0.028). The adherence of light ther- apy, in terms of the weekly total duration of light therapy ranged from 57% to 77% for all the participants. However, the appropriately-timed light therapy duration was lower, ranging from 33% to 62%. The adherence decreased with time but no group difference was observed. (eTable 1).

Primary outcomes

The cumulative rate of achieving remission was 67.4% and 46.7% in the BLT and DRL group respectively. Time to remission was shorter for the BLT group relative to the DRL group (log-rank test p = 0.024). To control for the female preponderance, gender was included as a covariate in the Cox proportional hazard sur- vival analysis, and patients in the BLT group had a higher prob- ability of achieving remission relative to patients in the DRL group [hazard ratio = 1.9 (95% CI = 1.13.4), p = 0.026]. (Fig. 2).

With regard to the clinician-rated depression severity, the 17-HDS was reduced over time in both groups (main effect of time, p < 0.001). There was a significant group effect (p = 0.044) with a lower 17-HDS across all time points in the BLT than the DRL group but the groups did not differ with respect to change in 17-HDS over time (group × time interaction, p = 0.107). The Cohend for the between-group effect size was 0.17 (Table 2).

Sensitivity analysis

We performed a sensitivity analysis (Table 2) focusing on those participants who had at least 50% adherence to the total duration of the prescribed light therapy. In total, 70 out of 93 participants

(75.3%) were included in the analysis (38 in BLT and 32 in DRL group, respectively). Baseline demographic and clinical char- acteristics did not differ between the two groups except for a higher SF36 score in the BLT group at baseline. Similar findings on a faster remission (log-rank test, p = 0.022) and a higher prob- ability of achieving remission [hazard ratio 2.0, (95% CI = 1.13.8), p = 0.027] was found in the BLT group. There was also a significant group × time interaction ( p = 0.04) on the 17-HDS observed, with a greater improvement in the BLT group. The Cohens d for the effect size was 0.19.

Secondary outcomes

For other secondary outcomes (HAM-A, HADS, ISI, BSSI, CFS, SF36), each of these assessments showed significant main effects of time but there were no significant group×time interaction effects (Table 3). Similar findings were observed in the sensitivity analysis (eTable 2).

Sleep parameters by sleep diary

Along with the gradual advance in light therapy timing, the sleep- wake pattern was also advanced gradually in the treatment weeks, but there was no group × time interaction in these parameters. (eTable 3).

Adverse events

The incidence of treatment-emergent adverse event (AE) was defined as a change from baseline to at least moderate severity (eTable 4). Blurring of vision (18%) and restlessness (12%) were 

significantly more common in the DRL group, and overall, the incidence of side effects was more commonly found in the DRL than BLT group. Two participants withdrew from the study because of adverse effects: one from DRL group complained of dry eye, another one from BLT group complained of blurring of vision. In both cases, the discomfort was transient and subsided rapidly. There was no treatment-emergent hypomania/mania in the study.


Our results showed that 5-week adjunctive bright light treatment with the gradual advance in timing produced a more rapid remis- sion and a higher cumulative rate of remission than the DRL group. With an average duration of depressive illness of 13.7 years, the participants in our study represented those who were difficult to treat and did not remit despite years of treatment. The findings from the present study showed that 5 weeks of BLT with the advance protocol could facilitate their remission of depression, the result was consistent with other light treatment trials of similar duration (Goel, Terman, Terman, Macchi, & Stewart, 2005; Martiny, 2004). In concordance with other earlier studies (Benedetti et al., 2003; Kripke, 1998), adjunctive light ther- apy showed a quick antidepressant effect, suggesting that antide- pressants and light therapy could work synergistically (Benedetti et al., 2003; Martiny, 2004). With the good tolerability, a lack of drugdrug interactions and relatively few contra-indications, our finding suggested that BLT with gradual timing advancement protocol could be a valuable adjunctive treatment for evening chronotyped depressed patients who did not improve with con- ventional therapy.

Although there was a parallel improvement of anxiety symp- toms, insomnia severity, suicidal ideation and fatigue over time, there were no significant differences between the two groups. The between-group effect sizes on the change of 17-HDS after 5 weeks of treatment was small (d=0.17 for primary analysis and 0.19 for sensitivity analysis). Compared to the similar small effect size of antidepressants (d=0.30) (Cipriani et al., 2018), the effect size of bright light therapy in this study might still be clinically meaningful as this group of evening-chronotype patients were more difficult to treat with poorer response to treatment (Chan et al., 2014). In addition, in the study by Lam et al., signifi- cant difference from placebo occurred only after 4 weeks (Lam et al., 2016). As the current study only had a modest treatment duration of 5 weeks, it may be possible that a longer duration 

of bright light treatment might lead to greater response. In contrast to a previous trial of adjunctive light thearpy (Benedetti et al., 2003), where the timing of placebo exposure was scheduled at 1.5 h after the optimal timing for the light ther- apy group to avoid the phase advance, the DRL group also under- went weeks of gradual advance in the timing of light therapy in our study as the prescriber of the current study was also blinded to treatment allocation. The bedtime, rise time and sleep mid- point were advanced during the study period in both groups. It has been shown that adherence to a fixed advanced sleep/wake schedule could result in significant circadian phase shifts in young adults with subclinical DSPD with or without morning blue light exposure (Sharkey, Carskadon, Figueiro, Zhu, & Rea, 2011). The timing of sleep and dim light melatonin onset (DLMO) was also advanced in the DSPD patients in the dim light group that were instructed to gradually advance wake time (Wilhelmsen-Langeland et al., 2013). It is possible that the advancement of sleep-wake pattern might have ameliorated the cir- cadian misalignment in the evening-chronotype patients in this study, which might, in turn, contribute to the improvement of clin- ical outcomes in both treatment groups. Nonetheless, even after controlling for the phase advance effect, the effect of bright light treatment was still evident, with a greater improvement in depres- sion especially in the adherent group. Further study would be needed to delineate the long-term treatment effect of gradual sleep phase advance, alone and in combination with bright light therapy and antidepressant treatment.

Apart from reducing circadian misalignment, it has been sug- gested that partial sleep deprivation could have contributed to the more rapid amelioration of depression seen in the bright light group (Benedetti et al., 2003). However, with the gradual advance- ment protocol in our study, both groups have similar advance in the sleep-wake pattern without incurring sleep deprivation. In addition, the insomnia severity as measured by ISI in both groups remained at the moderate range, irrespective of treatment modal- ities. This suggested that the mechanism of improving depression by bright light therapy might be independent of the effect of sleep deprivation or the improvement of insomnia. Interestingly, the antidepressive effect of BLT may also be independent to that of circadian effect by acting via the retino-raphe projection (from retinal ganglion cells to dorsal raphe nucleus) to modulate the serotoninergic tone directly (Ren et al., 2013). Nevertheless, the persistence of insomnia in this group of evening-type depressed patients further argues that insomnia itself would deserve an in- dependent, focused treatment. Future study should investigate the effects of the concurrent cognitive behavioral therapy for insomnia (CBT-I) in addition to BLT in treating insomnia and depression.

The adherence rate to the total duration of light therapy ranged from 57% to 77% in our study, whereas the reported adherence rate in another 5-week study (Martiny, 2004) (albeit without precise definition) was nearly 90%. However, the adher- ence to the appropriately-timed light therapy was 3562%, the suboptimal adherence in our study could be partially related to the recruitment of the patients with evening-chronotype, which was often associated with poorer self-regulation (Owens, Dearth-Wesley, Lewin, Gioia, & Whitaker, 2016), greater procras- tination (Digdon & Howell, 2008) and more irregular lifestyle (Monk, Buysse, Potts, DeGrazia, & Kupfer, 2004). The difficulty in motivating evening-chronotype patients in treatment repre- sents a clinical challenge. There is a need to explore additional ways (e.g. via motivational interviewing (Micic et al., 2019)) to 

improve adherence in futur research, in order to maximize the treatment benefits when providing light therapy in this unique clinical population.

Strengths and limitations

This was a double (prescriber and assessor) blinded randomized controlled trial which would have limited the potential bias from each party. We had a long follow-up period that was up to 5 months post-treatment. However, some limitations of this study should be noted. First, despite randomization, there was a slight female preponderance in the DRL group. We have further con- trolled this potential covariate, and previous studies also did not show any gender difference in the treatment response in light therapy (Lam, 1994; Leibenluft, Hardin, & Rosenthal, 1995). Second, the remission in this study was defined by a 17-HDS of seven or less. The symptomatic timeframe as assessed by 17-HDS was limited to the past 1 week. It could be possible that there was a fluctuation of depressive symptoms between the assessment timepoints, especially in the follow-up period. The relapse of symptoms was not captured in the survival analysis.


Our findings suggested that adjunctive bright light therapy with gradual advance timing protocol is effective in producing a quicker and better antidepressant effect in non-seasonal unipolar depressed patients with evening-chronotype.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291720003232

Acknowledgements. This project was supported by the Health and Medical Research Fund, The Food and Health Bureau, The Government of Hong Kong Special Administrative Region (Ref 12131131). The funder (The Food and Health Bureau, Hong Kong) of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Conflictofinterest. YunKwokWing-ReceivedpersonalfeesfromEisaiCo., Ltd for lecture, travel support from Lundbeck HK Limited, outside the submitted work. Others - none